A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).

doi:10.1158/1078-0432.CCR-21-3194

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2022

Hayashi Hidetoshi, Sugawara Shunichi, Fukuda Yasushi, Fujimoto Daichi, Miura Satoru, Ota Keiichi, Ozawa Yuichi, Hara Satoshi, Tanizaki Junko, Azuma Koichi, Omori Shota, Tachihara Motoko, Nishino Kazumi, Bessho Akihiro, Chiba Yasutaka, Haratani Koji, Sakai Kazuko, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhiko

Abstract excerpt

PURPOSE: Although the efficacy of programmed cell death-1 (PD-1) blockade is generally poor for non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) gene, EGFR tyrosine kinase inhibitors (TKIs) may improve the tumor immune microenvironment. We performed a randomized study to assess whether nivolumab improves outcome compared with chemotherapy in such patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Nivolumab

Share to Pemetrexed

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34921023
DOI: 10.1158/1078-0432.CCR-21-3194
PMCID: PMC9397372

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).PMID 34921023Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.Semantic proximity Read ↗

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.Semantic proximity Read ↗

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Semantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Nivolumab after cyclophosphamide and doxorubicin induction chemotherapy in previously treated patients with EGFR or ALK wild type non-squamous cell non-small cell lung cancer with less than 10% of PD-L1 expressionSemantic proximity Read ↗

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.Semantic proximity Read ↗

Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?Semantic proximity Read ↗

Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted (DA) EPOCH in Peripheral T-cell Lymphoma: A Phase I TrialSemantic proximity Read ↗

Nivolumab for unresectable cutaneous epithelial malignancies: An open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)Semantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.